Key Requirements of Annex 22 for AI Models in Regulated Environments
The pharmaceutical and life sciences sectors are currently a
major transformation in the way that technology supports manufacturing. As AI
and ML technologies are transitioning from research labs to production
facilities, regulators have bodies in to keeps in mind that innovation does not
put safety at risk. The publication of the Annex 22
guideline is a represents a landmark moment in this journey, being the first
well, articulated framework of how AI can be used in good manufacturing
practice (GMP) environments.
Understanding the nuances of Annex 22 is no longer optional
for Quality Assurance (QA) groups and information scientists; it's a
fundamental requirement for final compliant in an increasingly automated world.
Overview of Annex 22 Applicability to AI Models
Annex 22
was created to fill the void left
by old regulations, like Annex 11, which were mainly
concerned with traditional computer systems. In
contrast to regular software that operates on clearly defined, hard,
coded instructions, AI models develop their knowledge through
data. Because of this "learning" behavior introduces a level of
complexity that requires specific oversight.
The scope of Annex 22 is deliberate and risk-based.
It primarily applies to:
- Static
and Deterministic Models: In critical GMP applications-those that
directly affect patient safety or product quality-the law presently favors
models that offer the same output for the same input and do not
"self-evolve" in a live environment.
- Critical
vs. Non-Critical Systems: For structures that effect records integrity
or product release, the requirements are stringent. While Generative AI or
Large Language Models (LLMs) are usually confined from essential
operations, they may be used in non-crucial roles provided there is robust
human oversight.
Essentially, Annex 22 ensures that AI is treated not
as a "black box" but as a validated tool with a clearly defined
purpose.
Data Management and Quality Controls
In the world of AI, the version is only as reliable because
the facts used to build it. Annex 22 places a heavy emphasis on the integrity
and quality of datasets. It is longer enough to simply have "a lot of
data"; that facts must be representative of the real manufacturing
environment.
Key
Data Requirements include:
- Representativeness:
Training records must include all common and rare versions the model might
encounter, such as different shifts, raw material batches, or
environmental conditions.
- Traceability:
Every piece of data used for training, validation, and testing must be
traceable. This aligns with ALCOA+ principles, ensuring that data is
attributable, legible, and contemporaneous.
- Bias
Mitigation: Regulated users must document how they have identified and
mitigated potential biases in the data that could lead to incorrect or
unsafe decisions.
Development and Testing Controls for AI Models
The validation of an AI model under Annex 22 goes
beyond traditional software testing. The guideline introduces the concept of Test
Data Independency, which is perhaps the most critical technical
requirement.
- Independent
Testing: The data used to test the model’s performance must be
entirely separate from the data used to train it. This prevents
"overfitting," where a model performs perfectly on known data
but fails in the real world.
- Predefined
Metrics: Before testing begins, teams must define clear acceptance
criteria. This includes statistical measures such as accuracy,
sensitivity, specificity, and the F1 score.
- Explainability:
A core pillar of Annex 22 is that AI decisions must be explainable.
If a model flags a batch as "defective," the system should
provide enough transparency for a human operator to understand the logic
behind that flag.
Change Management and Lifecycle Controls
In a regulated environment, change is the only constant—but
it must be controlled. Annex 22 treats AI models as living entities that
require oversight throughout their entire lifecycle, from initial conception to
decommissioning.
Any change to the model structure, the underlying software,
or even a significant shift within the enter records assets have to cause a
Change Control process. This process involves a risk assessment to determine if
the change impacts the model's validated state. If a model needs to be
re-trained on new data to improve accuracy, this is not a "minor
update"; it is a significant event that may require a full or partial
re-validation to remain compliant with Annex 22.
Performance Monitoring and Requalification
Once an AI version is deployed, the work is far from over.
Annex 22 mandates continuous performance monitoring to detect "model
drift." Over time, changes in the production method (like new device or
different suppliers) can cause the model's accuracy to degrade.
To maintain compliance, companies must:
- Establish
Confidence Scores: Every AI-generated output has to ideally be
accompanied by a confidence score. If the score falls below a certain
threshold, the system should to trigger a human evaluation.
- Human-in-the-Loop
(HITL): For many programs, a qualified person should remain the final
decision-maker. This ensures that accountability stays with a human
professional in location of an algorithm.
- Periodic
Requalification: Much like a piece of lab equipment, AI models require
periodic assessments to ensure they still meet their intended use
requirements.
Conclusion
The arrival of Annex 22 marks a turning point for the
pharmaceutical industry. It moves AI from the world of "tech
projects" into the core of GxP compliance. By focusing on data integrity,
independent testing, and rigorous lifecycle management, the rule provides a
roadmap for companies to innovate safely. While the necessities are demanding,
they're designed to build trust-agree with that AI can actually make medicines
safer and approaches more efficient.
Comments
Post a Comment